Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies ; volume:36 ; number:5 ; day:26 ; month:7 ; year:2022 ; pages:625-637 ; date:9.2022
BioDrugs ; 36, Heft 5 (26.7.2022), 625-637, 9.2022
- Urheber
-
Cohen, Hillel P.
Hachaichi, Sohaib
Bodenmueller, Wolfram
Kvien, Tore K.
Danese, Silvio
Blauvelt, Andrew
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-022-00546-6
- URN
-
urn:nbn:de:101:1-2022120621512072711051
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cohen, Hillel P.
- Hachaichi, Sohaib
- Bodenmueller, Wolfram
- Kvien, Tore K.
- Danese, Silvio
- Blauvelt, Andrew
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar